Guru P. Sonpavde, Begoña P. Valderrama, Karim Chamie, Shilpa Gupta, Maria de Santis, Joydeep K. Banerjee, Laureen Ojalvo, Yixin Ren, Abhishek Bavle, Thomas Powles. "Phase 1/2 INTerpath-005 study: V940 (mRNA-4157) plus pembrolizumab with or without enfortumab vedotin (EV) for resected high-risk muscle-invasive urothelial carcinoma (MIUC).." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.5_suppl.tps893